推荐产品
![17:1 Lyso PS 1-(10Z-heptadecenoyl)-2-hydroxy-sn-glycero-3-[phospho-L-serine] (sodium salt), powder](/deepweb/assets/sigmaaldrich/product/structures/229/750/c333733e-eb96-4303-8bce-4f5ffb1bb637/640/c333733e-eb96-4303-8bce-4f5ffb1bb637.png)
![14:0 Cardiolipin (ammonium salt) 1′,3′-bis[1,2-dimyristoyl-sn-glycero-3-phospho]-glycerol (ammonium salt), chloroform](/deepweb/assets/sigmaaldrich/product/images/430/612/0f445fb1-937a-4275-bc4f-007d8a8a3328/640/0f445fb1-937a-4275-bc4f-007d8a8a3328.jpg)
方案
>99% (LPI; may contain up to 10% of the 2-LPI isomer, TLC)
表单
powder
包装
pkg of 1 × 100 μg (with stopper and crimp cap (850103P-100ug))
pkg of 1 × 500 μg (with stopper and crimp cap (850103P-500ug))
制造商/商品名称
Avanti Research™ - A Croda Brand 850103P
脂质类型
phosphoglycerides
运输
dry ice
储存温度
−20°C
SMILES字符串
[H][C@@](COP([O-])(O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](O)[C@H]1O)=O)(O)COC(CCCCCCCC/C=C\CCCCCC)=O.[NH4+]
InChI
1S/C26H49O12P.H3N/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-20(28)36-17-19(27)18-37-39(34,35)38-26-24(32)22(30)21(29)23(31)25(26)33;/h7-8,19,21-27,29-33H,2-6,9-18H2,1H3,(H,34,35);1H3/b8-7-;/t19-,21-,22-,23+,24-,25-,26-;/m1./s1
InChI key
VFLBJIAFDLNWCY-SNLSZFGJSA-N
一般描述
溶血磷脂酰肌醇（LPI）是磷脂酰肌醇（PI）的降解产物，是一种溶血磷脂亚种，在其头基中带有肌醇。
应用
17:1 Lyso PI（1-（10Z-十七碳烯酰基）-2-羟基-sn-甘油-3-磷酸-（1′-肌醇））已用作小鼠脑脂质组学LC-MS的内标。它可以用作内标，用于使用高效液相色谱/电喷雾电离串联质谱法（HPLC/ESI-MS）分析小鼠中的溶血磷脂酰肌醇（LPI），并使用液相色谱串联质谱（LC-MS-MS）系统检测定量分析慢性高脂饮食（HFD）喂养的WT和KO小鼠肝脏中的lysoPI（LPI）。
生化/生理作用
L-α-溶血磷脂酰肌醇（LPI）循环水平的升高与癌症相关，而且LPI是G蛋白偶联受体GPR55的有效配体。
溶血磷脂酰肌醇（LPI）充当生物活性溶血磷脂介体。它有利于静止的成纤维细胞的促有丝分裂活性。LPI具有在前脑缺血情况下区组海马神经元死亡的能力。
包装
带塞子和压接盖的2 mL棕色血清瓶（850103P-100ug）
带塞子和压接盖的2 mL棕色血清瓶（850103P-500ug）
法律信息
Avanti Research is a trademark of Avanti Polar Lipids, LLC
储存分类代码
11 - Combustible Solids
WGK
WGK 3
闪点(°F)
No data available
闪点(°C)
No data available
Ann-Christin Otto et al.
Biochimica et biophysica acta. Molecular and cell biology of lipids, 1864(5), 662-676 (2019-02-09)
A defect of hepatic remodeling of phospholipids (PL) is seen in non-alcoholic fatty liver disease and steatohepatitis (NASH) indicating pivotal role of PL metabolism in this disease. The deletion of group VIA calcium-independent phospholipase A2 (iPla2β) protects ob/ob mice from
Julien Masquelier et al.
Journal of pharmaceutical and biomedical analysis, 126, 132-140 (2016-05-22)
Increasing evidence suggests that lysophosphatidylinositols (LPIs), a subspecies of lysophospholipids, are important endogenous mediators. Although LPIs long remained among the less studied lysophospholipids, the identification of GPR55 as their molecular target sparked a renewed interest in the study of these
Atsushi Yamashita et al.
Prostaglandins & other lipid mediators, 107, 103-116 (2013-05-30)
Lysophosphatidylinositol (LPI) is a subspecies of lysophospholipid and is assumed to be not only a degradation product of phosphatidylinositol (PI), but also a bioactive lysophospholipid mediator. However, not much attention has been directed toward LPI compared to lysophosphatidic acid (LPA)
Tsukasa Yagi et al.
Cancers, 12(1) (2020-01-01)
Ovarian cancer remains a highly lethal disease due to its late clinical presentation and lack of reliable early biomarkers. Protein-based diagnostic markers have presented limitations in identifying ovarian cancer. We tested the potential of phospholipids as markers of ovarian cancer
Jordon M Inloes et al.
Biochemistry, 57(39), 5759-5767 (2018-09-18)
Deleterious mutations in the serine hydrolase DDHD domain containing 1 (DDHD1) cause the SPG28 subtype of the neurological disease hereditary spastic paraplegia (HSP), which is characterized by axonal neuropathy and gait impairments. DDHD1 has been shown to display PLA1-type phospholipase
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门